Zocere Board of Directors
President, New Mexico Angels
Managing Director, Phase One Ventures
John Chavez is president of and active investor in the New Mexico Angels. Under his leadership, the New Mexico Angels have seen an increase of more than 100 percent in investments in new companies. An avid entrepreneur, Chavez founded the New Mexico Start-Up Factory in 2012, a company that spins out technology start-ups based on innovations from the University of New Mexico. Chavez is managing director and founder of Phase One Ventures, based in Santa Fe, NM, a start-up fund aimed at bio and nanotechnologies. Additionally, he is president of Tafoya and Brainerd Partners LLC, a nationwide business development consulting firm.
Prior to this, Chavez was cabinet secretary of the Taxation and Revenue under New Mexico Governor Gary Johnson for six years and as president of the Federation of Taxation Administrators for one year. He is a member of the Board of Directors of the University of New Mexico Anderson School Foundation and the All Faiths Receiving Home Foundation. Chavez is a frequent guest lecturer on entrepreneurship and has addressed the International Economic Development Council annual summit and the 5th Annual Technology Transfer Conference by The Enterprise Center in Chattanooga, TN. He earned a BA in Economics, BBA in Finance, and an MBA from New Mexico State University.
Adrian N. Hobden, PhD
Retired Pharmaceutical Executive
Adrian Hobden has had a long and distinguished career in the global pharmaceutical industry. He earned his Bachelors and Masters degrees in Biochemistry from Cambridge University and a PhD in Molecular Biology from Leicester University, both in the United Kingdom (UK). After a postdoctoral fellowship with the Medical Research Council in the UK, he joined Glaxo as a research scientist. He was their first molecular biologist recruit worldwide and went on to run their Genetics Department and several other departments, including CNS Pharmacology. Hobden moved to the United States in 1996 and was responsible for Glaxo’s collaborations with biotechnology companies. In 1998, he joined Myriad Genetics in Salt Lake City as president of Myriad Pharmaceuticals. Myriad was later spun out as a public company called Myrexis with Hobden as CEO. Hobden, who retired in 2011, serves on the Board of Directors of Zocere and The Hope Fund for Cancer Research. He also is assisting a startup biotechnology company in New York studying cancer stem cells.
Hobden has been involved in development of a number of pharmaceuticals in a range of disease areas, including cancer, Alzheimer’s disease, cardiovascular, respiratory, HIV, and anti-fungals.
President and CEO
Wayne Laslie has more than 30 years of experience in pharmaceutical commercialization in U.S. and international markets.
He has served in positions of clinical development, business development and commercial development, along with sales, marketing and operations. Prior to joining Zocere, Inc., Laslie held increasingly responsible positions at Pfizer and predecessor companies of Sanofi-Aventis (now Sanofi); was executive vice president at Otsuka America Pharmaceuticals, and most recently he was the chief operating officer at Myriad Pharmaceuticals and Myrexis. Laslie is a former board member of the National Pharmaceutical Council and a past member of the University of Maryland’s Chancellor’s Advisory Committee.